Kristin Stephens - Feb 16, 2023 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role
Chief Development Officer
Signature
/s/ Todd Rosenthal, as attorney-in-fact
Stock symbol
SYRS
Transactions as of
Feb 16, 2023
Transactions value $
$0
Form type
4
Date filed
2/21/2023, 03:27 PM
Previous filing
Oct 11, 2022
Next filing
Apr 4, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYRS Restricted Stock Units Award $0 +35K $0.00 35K Feb 16, 2023 Common Stock 35K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock.
F2 These RSUs will vest as to one third (1/3rd) of the shares underlying the award on March 31, 2024 and as to an additional one third (1/3rd) of such shares at the end of each successive year thereafter.